trial · primary record
Deucravacitinib
Plaque Psoriasis
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 153 |
| Primary completion | 2033-09-08 |
| Primary endpoint | Observed average concentration at steady state for deucravacitinib at Week 2 |
| Registry ID | NCT04772079 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:01.675Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04772079
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.